Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664675 | 0.97 | HSD11B1 (0.42) | HSD11B1ALDH1A1KDM4ELTA4HMAPT | |
| SCHEMBL20325073 | 0.93 | HSD11B1 (0.40) | HSD11B1ALDH1A1KDM4ELTA4HMAPT | |
| SCHEMBL4893194 | 0.92 | HSD11B1 (0.47) | HSD11B1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6057032 | 0.92 | — | — | |
| SCHEMBL8149011 | 0.92 | HSD11B1 (0.47) | HSD11B1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3152433 | 0.91 | HSD11B1 (0.39) | HSD11B1ALDH1A1KDM4ELTA4HMAPT | |
| SCHEMBL21025901 | 0.91 | ALDH1A1 (0.47) | HSD11B1ALDH1A1KDM4ELTA4HMAPT | |
| SCHEMBL2916819 | 0.91 | CHKA (0.43) | HSD11B1KDM4EMEN1KMT2AHRH3 | |
| SCHEMBL22778298 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4ELTA4HMEN1KMT2A | |
| SCHEMBL13559781 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KDM4ELTA4HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 928 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867650-B1 | HYDROXYMETHYLBORON COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | claimed |
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| EP-1278735-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | claimed |
| US-7696347-B2 | Oxymethyl boron compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-13 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-20080242859-A1 | Oxymethyl Boron Compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-10-02 | — | — | US | claimed |
| EP-1867650-A1 | HYDROXYMETHYLBORON COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2007-12-19 | — | — | EP | claimed |
| US-7067522-B2 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2006-06-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB | 2005-04-28 | — | — | US | claimed |
| US-6838464-B2 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | claimed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | claimed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | AUBURN UNIVERSITY (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | US | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| EP-1278735-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001064656-A1 | 2,4,DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | HSD11B1 3762/4885ALDH1A1 2208/4885KDM4E 262/4885 |
| US-20030181474-A1 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | HSD11B1 4123/4885ALDH1A1 1046/4885KDM4E 862/4885 |
| US-20080242859-A1 | Oxymethyl Boron Compounds | BPGM, DDT, DBN1 | HSD11B1 805/4885ALDH1A1 1906/4885KDM4E 302/4885 |
| US-12043674-B2 | Synthetic cyclic peptides and methods of preparation and use thereof | VIP, PTMS, IAPP | HSD11B1 2754/4885ALDH1A1 4861/4885KDM4E 4155/4885 |
| US-20050090515-A1 | 2,4,DI (hetero-) arylamino (-oxy) -5-substituted pyrimidines as antineoplastic agents | CDK2, CDK4, CCNI | HSD11B1 4234/4885ALDH1A1 1393/4885KDM4E 712/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | HSD11B1 2164/4885ALDH1A1 299/4885KDM4E 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.